<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077099</url>
  </required_header>
  <id_info>
    <org_study_id>R5093-ONC-1863</org_study_id>
    <secondary_id>2019-001908-38</secondary_id>
    <nct_id>NCT04077099</nct_id>
  </id_info>
  <brief_title>REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the dose escalation (phase 1) part of the study is to assess the&#xD;
      safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum&#xD;
      tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in&#xD;
      patients with MET-altered Non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      The primary objective of the dose expansion (phase 2) part of the study is to assess&#xD;
      preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR)&#xD;
      per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">October 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Dose Limiting Toxicities</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs)</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAEs)</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of grade ≥3 laboratory abnormalities</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REGN5093 concentrations in serum over time</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) per RECIST 1.1</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR per RECIST 1.1</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1/Dose escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of TEAEs</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AESIs</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of SAEs</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of grade ≥3 laboratory abnormalities</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REGN5093 Pharmacokinetics (PK)</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REGN5093 concentrations in serum over time</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 2/Dose expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST 1.1.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per RECIST 1.1.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per RECIST 1.1.</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by Anti-drug antibodies (ADA) to REGN5093</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>REGN5093</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN5093</intervention_name>
    <description>Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.</description>
    <arm_group_label>REGN5093</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed NSCLC that is at advanced stage. Advanced is defined as&#xD;
             unresectable or metastatic disease. Patients must have exhausted all approved&#xD;
             available therapies appropriate for the patient.&#xD;
&#xD;
          -  Has available archival tumor tissue, unless discussed with the medical monitor.&#xD;
&#xD;
          -  Willing to provide tumor tissue from newly obtained biopsy. Newly obtained biopsies at&#xD;
             screening are required unless medically contra-indicated and discussed with the&#xD;
             medical monitor. For patients in expansion cohorts, biopsies should be taken from&#xD;
             tumor site which has not been irradiated previously and is not the only measurable&#xD;
             target lesion.&#xD;
&#xD;
          -  Previously documented presence of MET alterations: either MET-exon14 gene mutation&#xD;
             and/or MET gene amplification, and/or elevated MET protein expression, as defined in&#xD;
             the protocol.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Has received treatment with an approved systemic therapy or has participated in any&#xD;
             study of an investigational agent or investigational device within 2 weeks or 5&#xD;
             half-lives of the prior treatment whichever is shorter with a minimum of 7 days from&#xD;
             the first dose of study therapy&#xD;
&#xD;
          -  Has not yet recovered (i.e. grade ≤1 or baseline) from any acute toxicities resulting&#xD;
             from prior therapy except as described in the protocol&#xD;
&#xD;
          -  Has received radiation therapy or major surgery within 14 days of first administration&#xD;
             of study drug or has not recovered (i.e. grade ≤1 or baseline) from AEs, except for&#xD;
             laboratory changes as described in the protocol and patients with grade ≤2 neuropathy&#xD;
&#xD;
          -  For expansion cohorts only: prior treatment with MET-targeted biologic therapy&#xD;
             (function-blocking antibodies or ADCs)&#xD;
&#xD;
          -  For expansion cohorts only (except cohort 1A) prior treatment with any MET-targeted&#xD;
             agent including small molecule tyrosine kinase inhibitors eg, crizotinib, capmatinib,&#xD;
             tepotinib, as defined in the protocol&#xD;
&#xD;
          -  Untreated or active primary brain tumor, CNS metastases, leptomeningeal disease or&#xD;
             spinal cord compression as defined in the protocol&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Bordeaux Cedex 9</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Gyeonggi do</city>
        <state>Gyeonggi</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Facility</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MET (mesenchymal-epithelial transition factor)</keyword>
  <keyword>HGF (Hepatocyte Growth Factor)</keyword>
  <keyword>NSCLC (non-small cell lung cancer)</keyword>
  <keyword>MET-altered advanced</keyword>
  <keyword>Unresectable</keyword>
  <keyword>Metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

